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Objectives The aim of this study was to assess the role of transcatheter aortic valve implantation (TAVI) compared with
medical treatment (MT) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS)
at increased surgical risk.
Background Elderly patients with comorbidities are at considerable risk for SAVR.
Methods Since July 2007, 442 patients with severe AS (age: 81.7  6.0 years, mean logistic European System for Car-
diac Operative Risk Evaluation: 22.3  14.6%) underwent treatment allocation to MT (n  78), SAVR (n  107),
or TAVI (n  257) on the basis of a comprehensive evaluation protocol as part of a prospective registry.
Results Baseline clinical characteristics were similar among patients allocated to MT and TAVI, whereas patients allo-
cated to SAVR were younger (p  0.001) and had a lower predicted peri-operative risk (p  0.001). Unadjusted
rates of all-cause mortality at 30 months were lower for SAVR (22.4%) and TAVI (22.6%) compared with MT
(61.5%, p  0.001). Adjusted hazard ratios for death were 0.51 (95% confidence interval: 0.30 to 0.87) for
SAVR compared with MT and 0.38 (95% confidence interval: 0.25 to 0.58) for TAVI compared with MT. Medical
treatment (0.001), older age (80 years, p  0.01), peripheral vascular disease (0.001), and atrial fibrilla-
tion (p  0.04) were significantly associated with all-cause mortality at 30 months in the multivariate analysis.
At 1 year, more patients undergoing SAVR (92.3%) or TAVI (93.2%) had New York Heart Association functional
class I/II as compared with patients with MT (70.8%, p  0.003).
Conclusions Among patients with severe AS with increased surgical risk, SAVR and TAVI improve survival and symptoms
compared with MT. Clinical outcomes of TAVI and SAVR seem similar among carefully selected patients with
severe symptomatic AS at increased risk. (J Am Coll Cardiol 2011;58:2151–62) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.063Aortic stenosis (AS) is associated with poor prognosis once
symptoms ensue (1,2). Surgical aortic valve replacement
(SAVR) is the standard of care in the treatment of affected
patients by alleviating symptoms and improving survival
From the *Department of Cardiology, Swiss Cardiovascular Center, Bern University
Hospital, Bern, Switzerland; †Department of Cardiovascular Surgery, Swiss Cardio-
vascular Center, Bern, Switzerland; and the ‡Department of Anesthesiology, Bern
University Hospital, Bern, Switzerland; and the §Institute of Social and Preventive
Medicine and Clinical Trials Unit, Bern University Hospital, Bern, Switzerland. Dr.
Wenaweser is a proctor and receives honoraria from Medtronic CoreValve and
Edwards LifeSciences. Dr. Buellesfeld is a consultant for Medtronic. Dr. Khattab has
received speaker honoraria and proctor fees from Medtronic CoreValve and Edwards
LifeSciences. Dr. Eberle has received lecture honoraria from Medtronic CoreValve.(3–5). Despite favorable results even among high-risk pa-
tients, SAVR is not performed in up to one-third of eligible
patients, due to advanced age, comorbidities, previous car-
diac surgery, depressed left ventricular function, concomi-
Dr. Meier has received research grants from Medtronic and Abbott. Dr. Jüni is an
unpaid member of steering groups and executive committees of trials funded by
Abbott Vascular, Biosensors, Cordis, and Medtronic. Dr. Windecker has received
lecture and consultant fees from Edwards LifeSciences and Medtronic CoreValve.
All other authors have reported that they have no relationships relevant to the
contents of this paper to disclose. Drs. Wenaweser and Pilgrim contributed
equally to this work.Manuscript received February 17, 2011; revised manuscript received May 11, 2011,
accepted May 24, 2011.
2152 Wenaweser et al. JACC Vol. 58, No. 21, 2011
Severe AS and Treatment Modality November 15, 2011:2151–62tant coronary artery disease, and
patient refusal (5–18). Trans-
catheter aortic valve implantation
(TAVI) has been introduced as a
less-invasive treatment alterna-
tive and has been shown to reduce
mortality and repeat hospital stays
See page 2163
compared with a conservative
strategy among patients consid-
ered not to be suitable candidates
for SAVR (19). However, it re-
mains to be established how
many patients deemed inopera-
ble by cardiac surgeons might
indeed qualify for TAVI rather
than medical treatment (MT) in
routine clinical practice. More-
over, the role of TAVI among
patients found to be at increased
risk but still considered operable
by means of SAVR is unclear.
Several registries have shown
that TAVI is feasible with the
transfemoral, transapical, or sub-
clavian access with favorable re-
sults in terms of procedural suc-
cess, hemodynamic performance,
peri-procedural complications,
and survival (20–22). However,
paravalvular aortic regurgitation
is more frequent after TAVI
than SAVR, and long-term du-
rability of these valves is not yet established. Therefore,
selection of the most appropriate therapy among patients
with severe AS at increased risk remains difficult today.
Since the introduction of TAVI at our institution, all elderly
patients with severe AS at increased surgical risk undergo
systematic evaluation and subsequent treatment allocation
to MT, SAVR, or TAVI by an interdisciplinary team
consisting of interventional cardiologists and cardiac sur-
geons. The aim of the present study was to assess charac-
teristics of patients allocated to a particular treatment
strategy (MT, SAVR, TAVI) and to describe clinical
outcomes according to treatment selection during mid-term
follow-up.
Methods
Patient population. Since July 2007, all elderly patients
with symptomatic, severe AS deemed at increased surgical
risk were included in this prospective single-center registry.
Inclusion criteria were as follows: 1) symptomatic, severe AS
Abbreviations
and Acronyms
AS  aortic stenosis
CABG  coronary artery
bypass grafting
CI  confidence interval
CT  computed
tomography
ESV  Edwards Sapien
valve
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
MACCE  major adverse
cerebro-cardiovascular
event(s)
MCRS  Medtronic
CoreValve Revalving
system
MI  myocardial infarction
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coronary intervention
PRBC  packed red blood
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RIFLE  Risk, Injury,
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kidney disease
SAVR  surgical aortic
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TAVI  transcatheter aortic
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URL  upper reference
limitwith an echocardiographic mean gradient 40 mm Hg or acalculated aortic valve area1 cm2; and 2) age80 years in
the presence of a logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE) 15%. Patients
80 years of age were eligible if at least 1 of the following
comorbid conditions was present: previous cardiac surgery,
chronic obstructive pulmonary disease (forced expiratory
volume during 1 s 1.0), severe pulmonary hypertension
(60 mm Hg), porcelain aorta, history of radiation therapy
to the mediastinum, or frailty (body mass index 18
kg/m2). Exclusion criteria consisted of degenerated aortic
valve prostheses and severe aortic regurgitation in the
absence of AS. The study was approved by the local ethics
committee, and all subjects gave written, informed consent.
Evaluation and treatment allocation. All patients under-
went comprehensive evaluation with a standardized proto-
col during a short check-up hospital stay, including left and
right heart catheterization, aortography, transthoracic and
transesophageal echocardiography, and computed tomogra-
phy (CT) angiography of the chest, abdomen, and pelvis.
Clinical risk assessment was performed with the linear and
logistic EuroSCORE and Society of Thoracic Surgeons
Score (23). Patients with comorbid conditions including
malignancies, prior mediastinal radiation therapy, chronic
pulmonary disease, peripheral vascular disease, chronic renal
failure, previous cardiac surgery, liver cirrhosis, and bleeding
diathesis underwent subspecialty evaluation for complemen-
tary risk assessment and treatment recommendation. An
interdisciplinary team of interventional cardiologists and
cardiac surgeons reviewed the cases and formed a consensus
on treatment selection (MT, SAVR, or TAVI) on the basis
of individual risk assessment and anatomical and technical
considerations as well as patient preferences. Patients were
given time to think about the proposed treatment plan and
consult with their general practitioner and referring cardiolo-
gist. The final treatment allocation was eventually the result of
the recommendation as formulated by the Heart Team and
patient decision. Crossover from one treatment allocation to
another was possible as long as technically feasible.
Medical treatment comprised antithrombotic therapy for
treatment of concomitant coronary artery disease or atrial
fibrillation, antihypertensive drugs in case of arterial hyper-
tension, statins for treatment of hypercholesterolemia, and
diuretics for management of heart failure symptoms, rarely
complemented by digoxin. Percutaneous coronary intervention
(PCI) was performed in case of coronary artery disease with
limiting angina. Isolated balloon aortic valvuloplasty was not
performed as part of the MT strategy or as a bridge to SAVR
in patients with decompensated heart failure.
Surgical aortic valve replacement was performed through
a median sternotomy. Cardiopulmonary bypass was con-
ducted in moderate hypothermia, and myocardial protection
was performed with 100 ml of crystalloid cardioplegia
(Cardioplexol, SwissCardiotech, Bern, Switzerland). The aorta
was cross-clamped and opened at the level of the sino-
tubular junction. The leaflets were excised, and the aortic
annulus was carefully debrided. The annulus was sized with
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circumferentially through the annular tissue and the sewing
cuff of the bioprosthesis before the valve was lowered into
position.
Figure 1 Patient Flow According to CONSORT Statement
Patient flow according to CONSORT (Consolidated Standards for Reporting of Trials
and treatment allocation to medical treatment (Medical Rx), surgical aortic valve re
Figure 2 Reasons for Treatment Allocation
Reasons for treatment allocation are summarized in columns for each treatment s
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sota) or the Edwards SAPIEN valve (ESV) (Edwards Life-
sciences, Irvine, California), whereas only ESV was used for
transapical access. The algorithm for access and device selec-
tion according to annulus diameter and vascular access dimen-
sions was as follows: patients with an annulus size between 18
mm and 25 mm were treated preferentially with a transfemoral
ESV if the vascular access site diameter was 8 mm, whereas
a transfemoral MCRS was used in case of a vascular access site
diameter6 mm but8 mm. A transapical approach with the
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Overall
(n  442)
Age (yrs) 81.7 6.0 8
Women 230 (52.0%)
BMI (kg/m2) 25.6 4.6 2
Cardiac risk factors
Hypertension 338 (76.5%)
Current smoker 65 (14.7%)
Diabetes mellitus 101 (22.9%)
Positive family history for
coronary artery disease
78 (17.6%)
Hypercholesterolemia 233 (52.7%)
Past medical history
Prior MI 79 (17.9%)
Prior PCI 77 (17.4%)
CABG 76 (17.2%)
Previous stroke 44 (10.0%)
Peripheral vascular disease 93 (21.0%)
Symptoms
NYHA functional class
I 48 (10.9%)
II 142 (32.2%)
III 214 (48.5%)
IV 37 (8.4%)
Angina 157 (35.5%)
Syncope 51 (11.5%)
Cardiac rhythm
Atrial fibrillation 105 (23.8%)
Prior pacemaker 39 (8.8%)
Risk Assessment (%)
Log. EuroSCORE 22.3 14.6 2
Lin. EuroSCORE 10.2 2.5 1
STS score 6.0 5.0
Medications
Acetylsalicylic acid 254 (57.5%)
Clopidogrel 62 (14.0%)
Oral anticoagulation 114 (25.8%)
Diuretic 285 (64.5%)
Beta-blocker 206 (46.6%)
ACE inhibitor/ARB 203 (45.9%)
Calcium-channel blocker 53 (12.0%)
Statin 184 (41.6%)
Values are n (%) or mean SD, unless otherwise indicated. *Continuou
with Pearson’s chi-square test.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor
EuroSCORE  European System for Cardiac Operative Risk Evaluation
treatment; NYHANewYork Heart Association; PAS pulmonary artery systolic
replacement; STS  Society of Thoracic Surgeons; TAVI  transcatheter aortESV was preferred if the vascular access site was6 mm or in
the presence of excessive tortuosity or calcification of the
ilio-femoral vessels. Patients with an annulus size between 25
and 27 mm were only treated with the MCRS with a
transfemoral approach if the vascular access site diameter was
6 mm and via a trans-subclavian approach if the vascular
access site diameter was 6 mm.
The decision for coronary revascularization differed
omewhat between patients undergoing PCI as compared
ith those undergoing revascularization by coronary artery
78)
SAVR
(n  107)
TAVI
(n  257) p Value*
5.7 79.7 5.5 82.1 6.2 0.001
.3%) 53 (49.5%) 144 (56.0%) 0.09
3.5 26.0 4.7 25.8 4.9 0.03
.7%) 85 (79.4%) 201 (78.2%) 0.08
%) 16 (15.0%) 42 (16.3%) 0.27
.1%) 21 (19.6%) 62 (24.1%) 0.65
.4%) 17 (15.9%) 49 (19.1%) 0.65
.0%) 46 (43.0%) 155 (60.3%) 0.001
.5%) 9 (8.4%) 47 (18.3%) 0.001
.8%) 9 (8.4%) 58 (22.6%) 0.003
.1%) 4 (3.7%) 54 (21.0%) 0.001
.7%) 8 (7.5%) 23 (8.9%) 0.08
.5%) 13 (12.1%) 64 (24.9%) 0.03
0.10
%) 18 (16.8%) 23 (8.9%)
.6%) 41 (38.3%) 79 (30.7%)
.9%) 43 (40.2%) 131 (51.0%)
.4%) 5 (4.7%) 24 (9.3%)
.6%) 55 (51.4%) 75 (29.2%) 0.001
.9%) 13 (12.1%) 24 (9.3%) 0.11
.6%) 19 (17.8%) 66 (25.7%) 0.25
%) 9 (8.4%) 26 (10.1%) 0.39
14.5 12.5 8.2 24.7 24.9 0.001
2.2 8.3 2.0 10.7 2.5 0.001
4.1 4.8 5.3 6.4 5.0 0.009
.0%) 59 (55.1%) 156 (60.7%) 0.21
.8%) 5 (4.7%) 47 (18.3%) 0.003
.2%) 18 (16.8%) 74 (28.8%) 0.05
.1%) 48 (44.9%) 173 (67.3%) 0.001
.0%) 41 (38.3%) 133 (51.8%) 0.04
.3%) 53 (49.5%) 117 (45.5%) 0.61
%) 18 (16.8%) 29 (11.3%) 0.15
.9%) 33 (30.8%) 123 (47.9%) 0.006
les were compared with analysis of variance and categorical variables
rs; BMI  body mass index; CABG  coronary artery bypass grafting;
linear; Log.  logarithmic; MI myocardial infarction; MT medicalMT
(n 
3.2
33 (42
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symptomatic and the vast majority of patients did not have
noninvasive assessment of ischemia before cardiac catheter-
ization, the need of revascularization was based on angio-
graphic findings. Among patients undergoing CABG, all
vessels with a diameter stenosis50% and a reference vessel
diameter 2 mm were considered for revascularization by
eans of arterial or venous conduits if technically feasible.
mong patients undergoing PCI, the indication for revas-
ularization was more conservative. In general, a stenosis with
a diameter 70% by visual estimate in a major epicardial
oronary artery or large side branch (2.5 mm reference vessel
iameter) was considered clinically relevant. In addition, the
yocardial territory of the supplying vessel had to be viable as
ssessed by absence of akinesia in the left ventricular angio-
ram. Patients did not systematically undergo invasive assess-
ent of ischemia by use of fractional flow reserve, because
esults might be misleading in the presence of significant
entricular hypertrophy regardless of revascularization strategy.
ata collection. The date of the intervention was consid-
red the time of inclusion into the study among patients
ndergoing TAVI or SAVR. Among patients allocated to
T, the date of hospital stay for diagnostic cardiac cathe-
erization was determined as the inclusion time. Adverse
vents were assessed in hospital, and regular clinical
ollow-up was performed at 1, 6, and 12 months and yearly
hereafter by means of a clinical visit or a standardized
elephone interview. Between October 4, 2010, and No-
ember 29, 2010, we performed an additional follow-up for
ll patients with a follow-up duration below 30 months. For
atients with a suspected event, relevant medical records,
ischarge letters, and documentation of hospital stay were
ystematically collected from treating hospitals and physi-
ians in private practice. All suspected events were adjudicated by
n unblinded clinical event committee consisting of cardiac
urgeons and interventional cardiologists. Baseline clinical
nd procedural characteristics and all follow-up data were
ntered into a dedicated database, held at an academic
Imaging CharacteristicsTable 2 Imaging Characteristics
Overall
(n  442)
Echocardiography
LVEF (%) 52 14
Mean gradient (mm Hg) 45 17
AVA (cm2) 0.7 0.2
Cardiac catheterization
Coronary artery disease 270 (61.1%)
Mean gradient (mm Hg) 44 16
AVA (cm2) 0.5 0.2
PA systolic pressure (mm Hg) 52 18
PA systolic pressure 60 mm Hg 95 (21.5%)
Values are mean SD or n (%). *Continuous variables were compared
test.
AVA  aortic valve area; LVEF  left ventricular ejection fraction; PA  pulinical trials unit (CTU Bern, Bern University Hospital,
witzerland) responsible for central data audits and main-
enance of the database.
efinitions. Clinical adverse events were adjudicated by a
eam of interventional cardiologists and cardiac surgeons.
ardiovascular mortality was defined as any death due to a
roximate cardiac cause; unwitnessed death and death of
nknown cause were also recorded as cardiovascular as well
s all procedure-related deaths and death caused by non-
oronary vascular conditions such as cerebrovascular disease,
ulmonary embolism, or other vascular disease. Peri-
rocedural myocardial infarction (MI) was defined as new
schemic symptoms or signs in the presence of elevated
ardiac biomarkers (2 or more post-procedure samples that
ere 6 to 8 h apart with a 20% increase in the second
ample and a peak value exceeding 10 the 99th percentile
pper reference limit [URL] or a peak value exceeding 5
he 99th percentile URL with new pathological Q waves in
t least 2 contiguous leads) within 72 h after the index
rocedure. Spontaneous MI was recorded in case of detec-
ion of cardiac biomarkers 72 h after intervention with at
east 1 value above the 99th percentile URL, in conjunction
ith evidence of myocardial ischemia with at least 1 of the
ollowing: electrocardiographic changes indicative of new
schemia, new pathological Q waves in at least 2 contiguous
eads, or imaging evidence of new loss of viable myocardium
r new wall motion abnormality. Major stroke was deter-
ined in the setting of a rapid onset of focal or global
eurological deficit of 24 h duration, necessitating thera-
eutic intervention, or documentation of a new intracranial
efect with magnetic resonance imaging or CT scan. Tran-
ient ischemic attack was defined as a neurological deficit
ith complete regression within 24 h of onset. Major
dverse cerebro-cardiovascular events (MACCE) were de-
ned as death, MI, or major stroke. Kidney injury was based
pon changes in serum creatinine up to 72 h after the
rocedure and was defined in accordance with the modified
isk, Injury, Failure, Loss, End-stage kidney disease (RIFLE)
lassification. Stage 1 was determined as an increase of
T
78)
SAVR
(n  107)
TAVI
(n  257) p Value*
 16 57 12 51 14 0.001
 19 52 15 44 17 0.001
 0.2 0.6 0.2 0.7 0.2 0.82
0.3%) 56 (52.3%) 167 (65.0%) 0.08
 16 49 16 43 15 0.001
 0.2 0.5 0.2 0.5 0.2 0.14
 19 43 16 54 17 0.001
4.4%) 15 (14.0%) 61 (23.7%) 0.10
alysis of variance and categorical variables with Pearson’s chi-squareM
(n 
46
41
0.6
47 (6
38
0.6
57
19 (2
with anlmonary artery; other abbreviations as in Table 1.
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mol/l), stage 2 required an increase of the baseline creat-
inine of 200% to 300%, and stage 3 was considered in case
of an increase in creatinine of300% with an acute increase
of at least 44 mol/l. MACCE was defined as the compos-
te of all-cause death, major stroke, and MI in the present
tudy.
tatistical analysis. Continuous variables are presented as
ean  SD and were compared with analysis of variance.
ategorical data are expressed as frequency (percentages) and
Procedural DataTable 3 Procedural Data
Overall
(n  442)
General anesthesia 237 (53.6%)
Extracorporeal circulation 110 (24.9%)
Aortic valve intervention
Crossover to SAVR 3 (0.7%)
Crossover to TAVI 5 (1.1%)
Concomitant structural interventions
Mitral annuloplasty/MVR 2 (0.5%)
Tricuspid annuloplasty 1 (0.2%)
Aortic arch replacement 5 (1.1%)
ASD/PFO closure 6 (1.4%)
LAA occlusion 6 (1.4%)
Revascularization
Total revascularization 119 (26.9%)
Concomitant PCI 48 (10.9%)
Staged PCI 25 (5.7%)
CABG 46 (10.4%)
Hospital stay duration (days) 10.6 12.3
Valve-related outcome
Mean gradient (mm Hg) NA
Permanent pacemaker 65 (14.7%)
Valve-in-valve implantation 2 (0.5%)
Valve-in-series implantation 3 (0.7%)
Other valvular re-intervention 3 (0.7%)
Ventricular
perforation/tamponade
6 (1.4%)
Access site-related outcome
Deep soft tissue infection with
reconstructive surgery
1 (0.2%)
Re-thoracotomy 6 (1.4%)
Aortic dissection 2 (0.5%)
Vascular surgery 9 (2.0%)
Covered stent implantation 25 (5.7%)
Blood transfusions
Number of PRBC 0.9 2.1
2 PRBC 354 (80.1%)
2–3 PRBC 44 (10.0%)
4 PRBC 44 (10.0%)
Renal failure
RIFLE stage 1 57 (12.9%)
RIFLE stage 2 14 (3.2%)
RIFLE stage 3 12 (2.7%)
Values given are n (%) or mean  SD. *Continuous variables were c
chi-square test.ASD  atrial septal defect; LAA  left atrial appendage; MVR  mitral va
PRBC  packed red blood cells; RIFLE  Risk, Injury, Failure, Loss, End-stagere compared with the chi-square and Fisher exact tests.
urvival was estimated with the Kaplan-Meier method. All
urvival analyses were based on the initial treatment allocation,
n analogy to the intention-to-treat principle. Univariable and
ultivariable Cox proportional hazards models were used to
erive crude and adjusted survival estimates and to assess the
ssociation of baseline characteristics with clinical outcomes.
ll p values and 95% confidence intervals (CIs) are 2-sided. All
nalyses were performed with STATA (version 11, StataCorp,
ollege Station, Texas).
T
78)
SAVR
(n  107)
TAVI
(n  257) p Value*
.8%) 107 (100%) 127 (49.4%) 0.001
.3%) 107 (100%) 2 (0.8%) 0.001
.6%) NA 1 (0%) 0.08
.4%) 0 NA 0.001
0 2 (1.9%) 0 0.043
0 1 (0.9%) 0 0.21
0 5 (4.7%) 0 0.001
0 4 (3.7%) 2 (0.8%) 0.04
0 4 (3.7%) 2 (0.8%) 0.04
5.4%) 47 (43.9%) 60 (23.3%) 0.001
4.1%) 0 37 (14.4%) 0.001
.3%) 1 (0.9%) 23 (8.9%) 0.002
0 46 (43.0%) 0 0.001
A 15.0 20.2 10.1 11.6 0.001
A NA 8.7 4.5 NA
.3%) 4 (3.7%) 60 (23.3%) 0.001
0 0 2 (0.8%) 0.49
0 0 3 (1.2%) 0.34
0 0 3 (1.2%) 0.34
0 4 (3.7%) 2 (0.8%) 0.04
0 1 (0.9%) 0 0.21
.3%) 4 (3.7%) 1 (0.4%) 0.04
0 1 (0.9%) 1 (0.4%) 0.63
.3%) 0 8 (3.1%) 0.14
0 0 25 (9.7%) 0.001
 0.3 2.5 3.0 0.5 1.6 0.001
7.4%) 53 (49.5%) 225 (87.5%) 0.001
.6%) 21 (19.6%) 21 (8.2%) 0.001
0 33 (30.8%) 11 (4.3%) 0.001
.8%) 22 (20.6%) 32 (12.5%) 0.001
.3%) 11 (10.3%) 2 (0.8%) 0.001
.3%) 2 (1.9%) 9 (3.5%) 0.001
d with analysis of variance and categorical variables with Pearson’sM
(n 
3 (3
1 (1
2 (2
5 (5
12 (1
11 (1
1 (1
N
N
1 (1
1 (1
1 (1
0.06
76 (9
2 (2
3 (3
1 (1
1 (1
omparelve replacement; NA  not available; PFO  patent foramen ovale;
e kidney disease; other abbreviations as in Table 1.
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Treatment allocation. Between July 2007 and September
010, 452 patients with severe AS deemed at increased
urgical risk were evaluated. The screening examinations
ncluding cardiac catheterization and CT angiography re-
ulted in renal failure requiring hemodialysis in 2 patients
nd surgical revision of the vascular access site in 2 patients.
he delay between the evaluation visit and treatment by
ither SAVR or TAVI averaged 37  46 days (median 27
days) imposed mainly by delays in final patient decision.
Ten patients died during the time period between initial
evaluation and definitive treatment, leaving 442 patients for
the purpose of the present study (Fig. 1). Among these, MT
was selected in 78 (17.6%), SAVR in 107 (24.2%), and
Short-Term Clinical OutcomesTable 4 Short-Term Clinical Outcomes
At 30 Days
Medical
(n  78)
Surgical
(n  107)
TAV
(n  2
All-cause death 12 (15.4) 7 (6.5) 17 (6
Cardiovascular death 12 (15.4) 5 (4.7) 12 (4
MI 1 (1.3) 0 (0) 1 (0
Periprocedural MI 1 (1.3) 0 (0) 1 (0
Spontaneous MI 0 (0) 0 (0) 0 (0
Major stroke 1 (1.3) 4 (3.7) 10 (3
TIA 0 (0) 3 (2.8) 0 (0
All-cause death or major stroke 13 (16.7) 11 (10.3) 23 (9
All-cause death, major stroke, or MI 13 (16.7) 11 (10.3) 24 (9
Values are n (%) or crude hazard ratio (95% confidence interval). Continuity correction was used t
CI  confidence interval; HR  hazard ratio; MI  myocardial infarction; TAVI  transcatheter
Mid- and Long-Term Clinical OutcomesTable 5 Mid- and Long-Term Clinical Outcomes
Surgic
Medical Surgical TAVI Crude
At 12 months
All-cause death 43 (55.1) 20 (18.7) 44 (17.1) 0.29 (0.17–0.50
Cardiovascular death 42 (53.9) 11 (10.3) 31 (12.1) 0.17 (0.09–0.32
MI 1 (1.3) 0 (0) 4 (1.6) 0.24 (0.01–5.82
Major stroke 2 (2.6) 4 (3.7) 11 (4.3) 1.43 (0.26–7.82
TIA 0 (0) 3 (2.8) 0 (0) 5.26 (0.28–100
All-cause death or
major stroke
44 (56.4) 22 (20.6) 51 (19.8) 0.33 (0.19–0.54
All-cause death,
major stroke, or MI
44 (56.4) 22 (20.6) 53 (20.6) 0.33 (0.19–0.54
At 30 months
All-cause death 48 (61.5) 24 (22.4) 58 (22.6) 0.32 (0.20–0.53
Cardiovascular death 46 (59.0) 12 (11.2) 40 (15.6) 0.17 (0.09–0.31
MI 2 (2.6) 0 (0) 4 (1.6) 0.14 (0.01–2.92
Major stroke 3 (3.9) 5 (4.7) 11 (4.3) 1.12 (0.28–4.98
TIA 0 (0) 3 (2.8) 2 (0.8) 5.26 (0.28–100
All-cause death or
major stroke
49 (62.8) 26 (24.3) 64 (24.9) 0.35 (0.22–0.56
All-cause death,
major stroke, or MI
50 (64.1) 26 (24.3) 66 (25.7) 0.34 (0.21–0.54
Values are n (%) or hazard ratio (95% confidence interval). Continuity correction was used to estim
for age, sex, BMI, hypertension, current smoking, diabetes, stroke at baseline, peripheral arterial o
estimates could be calculated in case of 0 events in any of the comparison groups.
Abbreviations as in Tables 1 and 4.TAVI in 257 patients (58.1%) with use of transfemoral
access in 198 (44.8%), trans-subclavian access in 4 (0.9%),
and transapical access in 55 (12.4%) subjects. The reasons
for individual treatment allocation within the 3 groups are
shown in Figure 2. A considerable proportion of patients
allocated to MT (48.7%) were only at intermediate surgical
risk but refused to undergo SAVR or TAVI, despite the
recommendation of the Heart team. Patient baseline char-
acteristics are summarized in Tables 1 and 2. Patients
allocated to MT and TAVI were comparable in terms of
most baseline clinical characteristics and risk scores. Con-
versely, patients undergoing SAVR were younger (p 
.001); had better left ventricular function (p  0.001);
ower pulmonary arterial pressure (p  0.001); fewer pre-
Surgical vs. Medical TAVI vs. Medical
p Value for Difference
Among Groups
0.41 (0.16–1.05) 0.35 (0.16–0.75) 0.02
0.29 (0.10–0.83) 0.22 (0.09–0.53) 0.002
0.24 (0.01–5.82) 0.31 (0.02–4.92) 0.36
0.24 (0.01–5.82) 0.31 (0.02–4.92) 0.36
— — —
2.93 (0.33–26.2) 2.46 (0.31–19.7) 0.63
5.26 (0.28–100) — 0.02
0.62 (0.28–1.38) 0.42 (0.21–0.86) 0.06
0.62 (0.28–1.37) 0.45 (0.22–0.90) 0.08
ate relative risk in case of 0 cells, and the respective p values were based on Fisher exact test.
alve implantation; TIA  transient ischemic attack.
edical TAVI vs. Medical
p Value for Difference
Between Groups
Adjusted Crude Adjusted Crude Adjusted
0.47 (0.26–0.83) 0.25 (0.17–0.39) 0.32 (0.20–0.50) 0.001 0.001
0.29 (0.14–0.59) 0.18 (0.11–0.29) 0.21 (0.12–0.35) 0.001 0.001
1.10 (0.12–9.87) 0.53
1.35 (0.29–6.27) 0.91
0.035
0.51 (0.29–0.89) 0.28 (0.19–0.43) 0.34 (0.22–0.54) 0.001 0.001
0.50 (0.28–0.88) 0.30 (0.20–0.45) 0.36 (0.23–0.57) 0.001 0.001
0.51 (0.30–0.87) 0.32 (0.21–0.47) 0.38 (0.25–0.58) 0.001 0.001
0.29 (0.15–0.58) 0.22 (0.14–0.34) 0.25 (0.15–0.40) 0.001 0.001
0.54 (0.10–2.96) 0.25
0.91 (0.25–3.35) 0.89
1.54 (0.07–31.7) 0.42
0.55 (0.32–0.92) 0.34 (0.23–0.49) 0.39 (0.26–0.60) 0.001 0.001
0.51 (0.31–0.87) 0.34 (0.23–0.49) 0.39 (0.26–0.60) 0.001 0.001
ative risk in case of 0 cells, and the respective p values were based on Fisher exact test. Adjusted
disease at baseline, atrial fibrillation, left ventricular ejection fraction, PAS pressure. No adjustedI
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Severe AS and Treatment Modality November 15, 2011:2151–62vious cardiac surgery procedures, MI, and congestive heart
failure; and a lower peri-operative risk as assessed by the
linear and logistic EuroSCORE (p  0.001) and Society of
Thoracic Surgeons score (p  0.009), compared with both
MT and TAVI, but underwent myocardial revascularization
significantly more often. Crossover between treatment
groups was rare. Two patients initially allocated to MT
underwent SAVR after 238 and 290 days, respectively. Five
patients crossed over from MT to TAVI after 25, 244, 519,
710, and 833 days, respectively. One patient allocated to
TAVI underwent SAVR 3 days after unsuccessful prosthe-
sis deployment due to an exceedingly large annulus.
Procedural outcomes. Procedural data including revascu-
larization procedures and concomitant structural heart in-
terventions other than aortic valve replacement are shown in
Table 3. Concomitant coronary revascularization was per-
formed by means of CABG in 43.0% of patients selected for
SAVR and by means of PCI in 14.1% of patients allocated
to MT and in 14.4% of patients allocated to TAVI. The
mean hospital duration was 15.0  20.2 days for patients
undergoing SAVR and 10.1  11.6 days for patients
undergoing TAVI (p  0.001). A permanent pacemaker
was implanted in 1.3% of patients allocated to MT, 3.7% of
SAVR patients, and 23.3% of TAVI patients (p  0.001)
(MCRS 29.7% vs. ESV 12.0%; p  0.001). Surgical
re-exploration was necessary in 3.7% of SAVR patients (p
0.04), whereas TAVI patients underwent covered inguinal
stent implantation in 9.7% of cases (p 0.001) and inguinal
vascular surgery in 3.1% of cases (p  0.14). The mean
number of red blood cell transfusions was 0.06 0.3 packed
red blood cells (PRBC) in the MT, 2.5  3.0 PRBC in the
SAVR, and 0.5  1.6 PRBC in the TAVI group (p 
0.001). A RIFLE stage 3 renal failure was present in 1.3%
of medical, 1.9% of SAVR, and 3.5% of TAVI patients
(p  0.001). The mean transvalvular gradient after TAVI
was 8.7 4.5 mm Hg, and 28.3% of patients had more than
mild (grade 2) aortic regurgitation (grade 0/1: 9.4%,
grade 2: 62.3%, grade 3: 27.9%, grade 4: 0.4%).
Clinical outcomes. All comparisons referring to clinical
outcome are regarded as descriptive. The median follow-up
was 379 days (range 46 to 1,163 days) in SAVR patients,
377 days (range 34 to 1,165 days) in TAVI patients, and
643 days (range 204 to 1,290) in patients undergoing MT.
None of the patients was lost to follow-up. Event rates with
crude and adjusted hazard ratios for all major clinical
endpoints at 30 days, 12 months, and 30 months are
provided in Tables 4 and 5. Unadjusted rates of all-cause
mortality at 30 months were lower for patients undergoing
SAVR (22.4%) and TAVI (22.6%) compared with MT
(61.5%, p  0.001) (Fig. 3A). The adjusted hazard ratio for
death was 0.51 (95% CI: 0.30 to 0.87) for SAVR compared
with MT and 0.38 (95% CI: 0.25 to 0.58) for TAVI
compared with MT. Major stroke occurred with similar
frequency in all 3 groups with an adjusted hazard ratio of
1.12 (95% CI: 0.28 to 4.98) for SAVR compared with MT
and 0.91 (95% CI: 0.25 to 3.35) for TAVI compared withMT. Event rates for major adverse cardiac events and
MACCE were lower for both SAVR (24.3%) and TAVI
(25.7%) compared with MT (64.1%) with an adjusted
hazard ratio of 0.51 (95% CI: 0.31 to 0.87) for SAVR
compared with MT and 0.39 (95% CI: 0.26 to 0.60) for
TAVI compared with MT (Fig. 3B). A stratified analysis of
aortic valve replacement therapy (surgical or transcatheter)
compared with MT for all-cause mortality at 30 months
revealed consistent results across all studied subgroups
without evidence of a significant interaction (Fig. 4A).
Medical treatment, older age (80 years), peripheral vas-
cular disease, and atrial fibrillation at baseline were associ-
ated with all-cause mortality at 30 months in the multivari-
able regression analysis (Table 6). A stratified comparison
between TAVI and SAVR identified no significant differ-
ences between the 2 treatment strategies (Fig. 4B). Symp-
Figure 3 Unadjusted Survival Analysis and Incidence of
MACCE up to 30 Months of Follow-Up
(A) Cumulative incidence of all-cause mortality according to treatment strategy
up to 30 months of follow-up. Medical treatment (black line), surgical aortic
valve replacement (red line), transcatheter aortic valve implantation (TAVI)
(blue line). (B) Cumulative incidence of major adverse cerebro-cardiovascular
events (MACCE) defined as the combined endpoint of all-cause mortality, major
stroke, or myocardial infarction (MI) according to treatment strategy up to 30
months of follow-up. Medical treatment (black line), surgical aortic valve
replacement (red line), TAVI (blue line).tom status at various follow-up times is shown in Figure 5
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November 15, 2011:2151–62 Severe AS and Treatment ModalityFigure 4 Stratified Analysis for Mortality at 30 Months
(A) Stratified analysis for all-cause mortality in major subgroups undergoing intervention (surgical aortic valve replacement [SAVR] or transcatheter aortic valve implantation
[TAVI]) versus patients undergoing medical treatment. Black squares  hazard ratios (HR); horizontal black lines  confidence intervals (CI). An HR 1 (right side) is in favor
of medical treatment, whereas an HR 1 (left side) is in favor of intervention (SAVR or TAVI). (B) Stratified analysis for all-cause mortality in major subgroups undergoing SAVR
or TAVI. Black squares  HR; horizontal black lines  CI. An HR 1 (right side) is in favor of SAVR, whereas an HR 1 (left side) is in favor of TAVI. BMI  body mass index;
CABG  coronary artery bypass grafting; EuroSCORE  European System for Cardiac Operative Risk Evaluation; LVEF  left ventricular ejection fraction; PAS  pulmonary artery
systolic; STS  Society of Thoracic Surgeons.
ables 1
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TAVI but not among patients treated medically. At 1 year,
92.3% of patients undergoing SAVR and 93.2% of patients
undergoing TAVI were asymptomatic or had mild symp-
toms (New York Heart Association functional class I or II),
compared with 70.8% of patients treated medically (p for
difference between groups  0.003).
Discussion
This observational single-center study of treatment se-
lection and mid-term clinical outcomes among patients
with severe AS deemed at increased surgical risk shows
the following main findings: 1) patients allocated to MT
and TAVI had similar baseline clinical characteristics,
whereas patients undergoing SAVR were younger and
had lower perioperative risk scores but underwent coro-
nary revascularization more often; 2) MT of high-risk
patients with severe AS was associated with a dismal
prognosis; 3) aortic valve replacement therapy by means
of SAVR or TAVI resulted in improved survival and
symptom status compared with MT; and 4) all-cause
mortality and MACCE did not differ among patients
allocated to SAVR, compared with TAVI.
The patient population of the present study comprised
elderly (mostly octogenarians) patients with frequent co-
morbidities considered at increased risk for SAVR. Baseline
clinical characteristics of patients allocated to MT or TAVI
were much alike, whereas those undergoing SAVR were
somewhat younger and had less comorbidity, suggesting
that patients allocated to TAVI were mainly recruited from
the pool of patients formerly treated conservatively. Irre-
Predictors of All-Cause Mortality at 30 MonthsTable 6 Predictors of All-Cause Mortality at 30 Months
Alive Dead
Type of intervention
Medical 30 (9.6) 48 (36.9)
Surgical 83 (26.6) 24 (18.5)
TAVI 199 (63.8) 58 (44.6)
Age 80 yrs 211 (67.6) 101 (77.8)
Female 175 (56.1) 55 (42.3)
BMI 20 kg/m2 28 (9.0) 17 (13.1)
Hypertension 243 (77.9) 94 (73.4)
Current smoking 42 (13.5) 23 (18.0)
Diabetes 68 (21.8) 32 (25.0)
Hypercholesterolemia 173 (55.5) 59 (46.1)
History of CHD 192 (61.5) 80 (63.5)
History of MI 47 (15.1) 31 (24.2)
History of CABG 52 (16.7) 23 (18.0)
History of stroke 22 (7.1) 22 (17.3)
History of PAD 49 (15.7) 44 (34.4)
History of atrial fibrillation 63 (20.2) 42 (32.3)
LVEF 50% 78 (25.0) 49 (37.7)
Pulmonary arterial pressure 60 mm Hg 59 (18.9) 35 (26.9)
Values are n (%) unless otherwise indicated.
CHD  congenital heart disease; PAD  peripheral arterial disease; other abbreviations as in Tspective of the treatment allocation to either SAVR orTAVI, the long-term survival of patients undergoing inter-
vention for severe AS was improved, as compared with
patients allocated to MT in general as well as across most
patient subgroups (Fig. 4A). The benefit in terms of survival
with both SAVR and TAVI was associated with a sustained
improvement in symptom status (Fig. 5).
Several previous studies have highlighted the poor out-
come of patients with severe AS treated conservatively
(2–5). Recently, TAVI has been shown to lower mortality
from 51% to 31% and repeat-hospital-stay rate from 44% to
22%, compared with MT, in a randomized trial of elderly
patients with severe AS considered not to be suitable
candidates for SAVR (19). The present study confirms the
dismal prognosis of patients treated conservatively and
extends the findings to a contemporary patient population
with consideration of all currently available treatment op-
tions. Furthermore, it represents a cohort of consecutive and
unselected patients referred to a tertiary care center with
extended follow-up to 30 months. Similar to the results of
the PARTNER B (Placement of AoRtic TraNscathetER
Valve Trial) (19), the observed treatment effect in terms
of mortality was large (50% relative risk reduction) for
both crude and adjusted outcome variables, and the risk of
peri-procedural complications associated with TAVI and
SAVR did not exceed short-term mortality among patients
allocated to MT. Moreover, surgical and transcatheter aortic
valve replacement were associated with marked and sustained
improvement in quality of life as compared with MT. Of note,
all patients had been referred for evaluation of a possible
intervention, and the reason for a conservative strategy was
patient refusal of any procedure despite recommendation of an
ude HR (95% CI) p Value Multivariable HR (95% CI) p Value
0.001 0.001
Reference Reference
.32 (0.20–0.53) 0.46 (0.26–0.81)
.32 (0.21–0.47) 0.37 (0.24–0.57)
.43 (0.94–2.16) 0.09 1.64 (1.02–2.65) 0.041
.62 (0.44–0.88) 0.008 0.70 (0.46–1.05) 0.09
.25 (0.73–2.15) 0.41 1.30 (0.74–2.28) 0.37
.87 (0.58–1.29) 0.48 0.84 (0.53–1.32) 0.45
.03 (0.65–1.64) 0.89 1.28 (0.79–2.08) 0.32
.17 (0.78–1.76) 0.44 1.39 (0.88–2.19) 0.16
.72 (0.51–1.03) 0.07 0.76 (0.52–1.13) 0.17
.16 (0.80–1.67) 0.44 1.04 (0.68–1.59) 0.87
.45 (0.96–2.18) 0.08 0.99 (0.62–1.58) 0.96
.15 (0.73–1.81) 0.56 0.72 (0.41–1.24) 0.23
.18 (1.37–3.46) 0.001 1.51 (0.91–2.49) 0.11
.10 (1.43–3.03) 0.001 2.52 (1.67–3.81) 0.001
.71 (1.18–2.48) 0.004 1.51 (1.02–2.23) 0.04
.71 (1.20–2.45) 0.003 1.46 (0.97–2.20) 0.07
.49 (1.01–2.21) 0.04 1.39 (0.91–2.13) 0.13
, 2, and 3.Cr
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1invasive treatment strategy in the majority of cases. This
2161JACC Vol. 58, No. 21, 2011 Wenaweser et al.
November 15, 2011:2151–62 Severe AS and Treatment Modalityobservation is further substantiated by the similarity of patient
characteristics and risk scores among patients allocated to MT
and TAVI and suggests that TAVI addresses an unmet clinical
need.
Only limited evidence exists for the comparison of TAVI
with SAVR to date. In a 2-center study of 1,122 patients
comparing TAVI (n  114) with SAVR (n  1008),
patients undergoing TAVI were older and had heart failure
more frequently, a higher logistic EuroSCORE, and more
comorbidities. Crude mortality at 30 days was 9.6% for
TAVI and 2.3% for SAVR (odds ratio: 4.57, 95% CI: 2.2 to
9.7). The adjusted odds ratio of 30-day mortality ranged
from as low as 0.6 to as high as 7.6, depending on the
method used precluding any definitive conclusions as to the
relative safety of the 2 procedures (24). A propensity-score
Figure 5
NYHA Functional Class at Baseline Evaluation
and During Follow-Up to 1 Year According to
Treatment Strategy
AVI  aortic valve implantation; AVR  aortic valve replacement;
NYHA  New York Heart Association.matched analysis of 100 paired patients undergoing eithertransapical TAVI or SAVR reported similar survival rates at
1 year (TAVI: 73  4%, SAVR: 69  5%, p  0.55) (25).
Descoutures et al. (26) reported clinical outcome among 66
consecutive patients with severe AS after allocation to MT,
SAVR, and TAVI. At 6-month follow-up, mortality among
discharged patients amounted to 29% among MT patients,
whereas all patients treated by TAVI or SAVR had sur-
vived. In the present study, we observed differences in the
rate and type of peri-procedural complications between
SAVR and TAVI. Patients undergoing TAVI more fre-
quently suffered from atrioventricular conduction distur-
bances requiring permanent pacemaker implantation and
had a higher rate of aortic regurgitation, access site compli-
cations, and RIFLE stage 3 renal failure, whereas patients
undergoing SAVR more frequently required re-exploration
and had more blood transfusions and longer hospital stays.
However, mortality, major stroke, and MACCE occurred with
similar frequency among patients allocated to TAVI and
SAVR for both crude and adjusted outcomes during long-term
follow-up. The findings for the comparison of TAVI with
SAVR in terms of mortality were consistent across major
subgroups, although the results have to be interpreted with
caution in view of the limited sample size (Fig. 4B).
The first randomized comparison of TAVI and SAVR
among high-risk patients with severe AS revealed similar
outcomes in terms of mortality at 1 year (27). The present
study not only corroborates these findings in a nonrandom-
ized case series but also extends the observation to a
follow-up duration of 30 months in a large, consecutive, and
therefore unselected patient population as encountered in
routine clinical practice. Nevertheless, the higher rate of
paravalvular aortic regurgitation after TAVI and the uncer-
tain long-term durability of percutaneously implanted valve
prostheses require further scrutiny.
Study limitations. First, enrollment of patients into this
registry was based on referral from a primary or secondary
care facility with the primary intention of an active treat-
ment for severe AS, hence forestalling a certain selection of
patients potentially qualifying for an intervention. Second,
the data were acquired in a single tertiary care center, and
results might not be generalizable to institutions with
different referral patterns and collaborations between inter-
ventional cardiologists and cardiac surgeons. Third, this was
not a randomized comparison between MT, SAVR, and
TAVI, and therefore the results might be regarded as
descriptive. However, treatment effects in favor of SAVR
and TAVI as compared with MT were large, and findings
were robust after adjustment for differences in baseline
clinical characteristics. Moreover, the study provides out-
come data for all treated patients and therefore represents
treatment decision and outcomes of unselected patients as
encountered in routine clinical practice. Fourth, revascular-
ization was more commonly performed among patients
undergoing SAVR than among those allocated to TAVI. It
is well known that SAVR combined with revascularization
is associated with an increased risk as compared with
2162 Wenaweser et al. JACC Vol. 58, No. 21, 2011
Severe AS and Treatment Modality November 15, 2011:2151–62isolated valve replacement. Nevertheless, our data do not
allow distinction of whether revascularization was required
on the basis of objective evidence of ischemia or just
performed as part of a surgical strategy to revascularize any
vessel with a diameter stenosis 50%. The need of con-
comitant revascularization among patients with severe AS
undergoing TAVI requires careful study and is part of
ongoing investigations.
Conclusions
Among high-risk patients with severe AS, SAVR and
TAVI improve survival and symptoms, compared with MT.
Clinical outcomes of TAVI and SAVR seem similar among
carefully selected high-risk patients with severe AS.
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